Cachexia Clinical Trial
Official title:
Attenuation of Sarcopenia Using Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients: A Pilot Randomized Controlled Trial (PIVOT)
A Pilot Randomized Controlled Trial (RCT) will be conducted where where mechanically ventilated patients will be randomized to optimal protein (Achieve 80% protein supplementation adequacy with daily titration) versus standard protein feeding. Both groups will receive standard usual early exercise therapy. Specific aim 1: To determine if optimal protein supplementation improves functional outcome of patients as measured by Functional Status Score (FSS) on Day 7. Specific aim 2: To determine if optimal protein supplementation reduces muscle loss of patients at Day 7 as measured by the Rectus Femoris thickness and cross-sectional area (RFCSA) using skeletal muscle ultrasound. Specific aim 3: To determine difference in functional recovery between groups using quality of life (QOL) scores and 6-minute walk distance at 3 months after hospital discharge. The hypothesis is protein inadequacy can be overcome with optimized protein supplementation to reduce muscle loss/sarcopenia and functional impairment in ICU survivors.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | September 30, 2023 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. Age 21 years and above. 2. Expected mechanical ventilation duration = 48 hours. 3. Expected to stay in hospital for = 4 days. Exclusion Criteria: 1. Pregnant woman. 2. Amputation of either lower limbs. 3. Surgery of lower limb during the current admission. 4. 4. Any neurological/rheumatologic/orthopaedic/burn/trauma/physiological problem with feeding difficulties during 48h of intubation 5. Wheelchair-bound, walking aids and ADL-dependent. 6. Patient not able to feed by 48 hours AND not given parenteral feeding. 7. Patients on Continuous Renal Replacement Therapy. 8. Sepsis with poor prognosis. 9. Competing trial 10. Moribund within 48hours. 11. COVID-19 patients. 12. Declined to participate the study |
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Hospital, Singapore | National University of Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional Status Score for ICU (FSS-ICU) | It is an ordinal score consisting of 5 activities (namely, Rolling in bed, Supine to Sit Transfer, Sit to Stand Transfer, Sitting Edge of Bed, Walking); each activity is scored from 0 to 7 to a total of 35. A higher score indicates a better functioning. It closely resembles Activities of Daily Living (ADL) and it is possible to even measure the pre-admission score. The FSS-ICU is measured at day 1 upon recruitment and compared to a one week period and to the time of discharge in intensive care to determine functional improvements at these time points. | Day 1 of Randomisation; Day 7 of Randomisation; Day of ICU Discharge , approximately 14 days after ICU admission | |
Secondary | Rectus Femoris Cross-Sectional Area (RFCSA) and anterior thigh and rectus femoris thickness | RFCSA correlates well with quadriceps strength, measured by B-mode ultrasonography using linear transducer array. Pennation angle will also be calculated. The rectus femoris RFCSA and thigh thickness and pennation angle is measured at day 1 upon recruitment and compared to day 4 and then day 7 of study recruitment to determine changes in muscle loss. | Day 1 of Randomisation; Day 4 of Randomisation; Day 7 of Randomisation; Day of ICU Discharge , approximately 14 days after ICU admission | |
Secondary | Six-Minute Walk Test (6MWT) | Feasible standard measure of exercise capacity | 3 months post hospital discharge | |
Secondary | Clinical Frailty Index (CFI) | The CFI scoring is a scale from 1 to 9, 1 being very fit (best outcome) while 9 being terminally ill (worst outcome). The CFI is measured at day 1 upon recruitment and compared to point of ICU discharge to determine changes in frailty. | Day 1 of Randomisation; Day of ICU Discharge , approximately 14 days after ICU admission | |
Secondary | Blood Biomarkers | The following cytokines; IL-6, IL-10, IL-12 and TNF-1a and MCP1, HMGB1 will be analysed via blood test to monitor inflammatory reactions | Day 1 of Randomisation; Day 4 of Randomisation | |
Secondary | Indirect calorimetry (IC) | Gold standard for measurement of energy expenditure (EE) | Day 1 to Day 7 of Randomisation (daily or till extubation) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Completed |
NCT01696604 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT02567773 -
Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
|
Phase 1 | |
Completed |
NCT00866970 -
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
|
Phase 2 | |
Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
Completed |
NCT00031785 -
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
|
Phase 3 | |
Withdrawn |
NCT02017925 -
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
|
N/A | |
Recruiting |
NCT01829880 -
Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT01692990 -
Study on the Effect of Fish Oil and Appetite
|
Phase 0 | |
Completed |
NCT01419145 -
A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study
|
N/A | |
Terminated |
NCT00851448 -
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients
|
N/A | |
Completed |
NCT00994669 -
Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
|
N/A | |
Completed |
NCT01015274 -
Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
|
||
Terminated |
NCT00962234 -
Metabolism of Lipids in Advanced Cancer
|
N/A | |
Completed |
NCT00972634 -
Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer
|
N/A | |
Terminated |
NCT00535015 -
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00558558 -
Haelan and Nutrition in Cancer Patients
|
Phase 2 | |
Withdrawn |
NCT00163072 -
Pharmacokinetics and Safety of Transdermal Megestrol Acetate
|
Phase 4 |